Browsing Clinical Studies by author "Yap, Timothy"
Now showing items 1-8 of 8
-
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii, S; Gourley, C; Kumar, R; Geuna, E; Ern Ang, J; et al. (2017-07)Background The PARP inhibitor olaparib was recently granted Food and Drug Administration (FDA) accelerated approval in patients with advanced BRCA1/2 mutation ovarian cancer. However, antitumor responses are observed in ... -
CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer.
Lim, JSJ; Turner, NC; Yap, TA (2016-07)Patnaik and colleagues report on the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of abemaciclib for the treatment of advanced solid cancers, demonstrating antitumor activity in advanced breast ... -
Emerging biomarkers for PD-1 pathway cancer therapy.
Lim, JS; Sundar, R; Chénard-Poirier, M; Lopez, J; Yap, TA (2017-01)The field of immuno-oncology has witnessed unprecedented success in recent years, with several PD=1 and PD-L1 inhibitors obtaining US FDA registration and breakthrough drug therapy designation in multiple tumor types. ... -
Immuno-oncology combinations: raising the tail of the survival curve.
Harris, SJ; Brown, J; Lopez, J; Yap, TA (2016-06)There have been exponential gains in immuno-oncology in recent times through the development of immune checkpoint inhibitors. Already approved by the U.S. Food and Drug Administration for advanced melanoma and non-small ... -
Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre.
O'Carrigan, B; Lim, JSJ; Jalil, A; Harris, SJ; Papadatos-Pastos, D; et al. (2018-10-15)Background Greater understanding of the molecular classification of breast cancer has permitted the development of rational drug design strategies. In a phase I clinical trial setting, molecular profiling with next-generation ... -
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
Brown, JS; O'Carrigan, B; Jackson, SP; Yap, TA (2017-01)Germline aberrations in critical DNA-repair and DNA damage-response (DDR) genes cause cancer predisposition, whereas various tumors harbor somatic mutations causing defective DDR/DNA repair. The concept of synthetic lethality ... -
Targeting the PD-1/PD-L1 axis in non-small cell lung cancer.
Kumar, R; Collins, D; Dolly, S; McDonald, F; O'Brien, MER; et al.The last decade has witnessed rapid advances in the discovery and development of immune checkpoint inhibitors in cancer medicine, particularly drugs targeting programmed cell death 1 (PD-1) and programmed cell death ligand ... -
Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics.
Collins, DC; Sundar, R; Lim, JSJ; Yap, TA (2017-01)Precision medicine continues to be the benchmark to which we strive in cancer research. Seeking out actionable aberrations that can be selectively targeted by drug compounds promises to optimize treatment efficacy and ...